Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Schedule an appointment today


Major Research Achievements in Our History

1982 – Jeffrey Blumer, MD, establishes the hospital’s Center for Drug Research –one of the nation’s first pediatric clinical pharmacology and basic research programs.

1990 – Two children receive revolutionary gene therapy for an immune deficiency disorder at UH Rainbow Babies & Children’s Hospital – the first in the world.

1991-1994 – Hospital physicians participate in a national clinical study which demonstrates that hydroxyurea is an effective drug in preventing painful episodes of sickle cell disease.

1995 – Hospital physician performs the region’s first bone marrow transplant using umbilical cord blood.

1996 – Pediatric neurosurgeons help develop miniaturized tools for performing endoscopic brain surgery, reducing the need for open-skull surgery.

1999 – The hospital launches the Center for Bloodless Medicine and Surgery, becoming the first freestanding pediatric hospital in the nation to develop a bloodless program for children.

2011 – The Char and Chuck Fowler Family Foundation donates a $17 million transformational gift to establish the Angie Fowler Adolescent & Young Adult Cancer Institute at UH Rainbow Babies & Children’s Hospital.

2013 – Michele Walsh, MD, MS, leads pediatric efforts of the Ohio Perinatal Quality Collaborative to improve care and outcomes in Ohio by reducing bloodstream infections in hospitalized premature infants and near-term deliveries without medical indications. These efforts have reduced infections and NICU admissions, saving Ohio at least $11 million annually.

Angie’s Garden
Angie’s Garden

2016 – Angie’s Garden - a 7,500 sq. foot healing garden for patients, parents and staff - opens on the rooftop of UH Rainbow Babies & Children’s Hospital.

2017 – MedPacto partners with UH for first IO trial

2018 – Celloram spins-off DC technology (Letterio lab)

2019 – TheraCanVac signs agreement with Celloram; Almac to manufacture neo-antigen peptides